On 30 January 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Tybost. The marketing authorisation holder for this medicinal product is Gilead Sciences Ireland UC. 

Jan. 31, 2020 8:55 AM ET|About: Gilead Sciences, Inc. (GILD)|By: Douglas W. House, SA News Editor  

 https://seekingalpha.com/news/3536860-european-advisory-group-backs-expanded-label-for-gileads-tybost 

 https://www.gilead.com/-/media/files/pdfs/medicines/hiv/tybost/tybost_pi.pdf 

 https://seekingalpha.com/symbol/GILD 

Fri January 31, 2020 6:00 AM|GlobeNewswire|About: CYDYGlobeNewswire

VANCOUVER, Washington, Jan. 31, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (CYDY)

 https://www.cytodyn.com/ 

 https://www.cytodyn.com/pipeline/cancer 

 https://seekingalpha.com/symbol/CYDY 

 On 30 January 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product MabThera. The marketing authorisation holder for this medicinal product is Roche Registration GmbH. 

Jan. 31, 2020 8:11 AM ET|About: Roche Holding AG (RHHBY)|By: Douglas W. House, SA News Editor  

 https://seekingalpha.com/news/3536828-european-advisory-group-backs-expanded-use-of-roches-mabthera 

 https://seekingalpha.com/symbol/RHHBY 

 On 30 January 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Rezolsta. The marketing authorisation holder for this medicinal product is Janssen-Cilag International NV. 

Jan. 31, 2020 8:41 AM ET|About: Johnson & Johnson (JNJ)|By: Douglas W. House, SA News Editor  

 https://seekingalpha.com/news/3536851-european-advisory-group-backs-expanded-use-of-j-and-js-rezolsta 

 https://seekingalpha.com/symbol/JNJ 

 https://www.medicines.org.uk/emc/product/3466/smpc 

 On 30 January 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Suliqua. The marketing authorisation holder for this medicinal product is sanofi-aventis groupe. 

Jan. 31, 2020 8:48 AM ET|About: Sanofi (SNY)|By: Douglas W. House, SA News Editor  

 https://seekingalpha.com/news/3536853-european-advisory-group-backs-updated-labeling-for-sanofis-suliqua 

 https://seekingalpha.com/symbol/SNY 

Fri January 31, 2020 8:00 AM|Business Wire|About: SGEN

- Application Supported by Results of Pivotal HER2CLIMB Trial -

- First Investigational Therapy in a Pivotal Trial to Include Patients with Metastatic HER2-Positive Breast Cancer with Active Brain Metastases -

- EU Marketing Authorization Application (MAA) Follows Recent Submission of Tucatinib New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) -

BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (SGEN)

 https://clinicaltrials.gov/ct2/show/NCT03975647?term=tucatinib&draw=3 

 https://www.seattlegenetics.com/ 

 https://www.businesswire.com/news/home/20200131005084/en/ 

 https://www.seattlegenetics.com/pipeline/tucatinib 

 On 30 January 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Staquis, intended for the treatment of atopic dermatitis. The applicant for this medicinal product is Pfizer Europe MA EEIG. 

Jan. 31, 2020 7:37 AM ET|About: Pfizer Inc. (PFE)|By: Douglas W. House, SA News Editor  

 https://seekingalpha.com/news/3536796-european-advisory-group-backs-pfizers-crisaborole-for-atopic-dermatitis 

 https://seekingalpha.com/symbol/PFE 

 https://www.pfizer.com/ 

 On 30 January 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Rybelsus, intended for the treatment of type 2 diabetes. The applicant for this medicinal product is Novo Nordisk A/S. 

Jan. 31, 2020 7:32 AM ET|About: Novo Nordisk A/S (NVO)|By: Douglas W. House, SA News Editor  

 https://seekingalpha.com/news/3536782-european-advisory-group-backs-novos-semaglutide-for-t2d 

 https://seekingalpha.com/symbol/NVO 

 https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-rybelsus_en.pdf 

Fri January 31, 2020 7:15 AM|PR Newswire|About: ABBV

PR Newswire

NORTH CHICAGO, Ill., Jan. 31, 2020 /PRNewswire/ -- AbbVie (ABBV)

 https://www.abbvie.com/ 

 https://www.prnewswire.com/news-releases/abbvie-receives-positive-chmp-opinion-for-maviret-glecaprevirpibrentasvir-to-shorten-treatment-duration-to-eight-weeks-in-genotype-3-treatment-naive-patients-with-chronic-hepatitis-c-and-compensated-cirrhosis-300996801.html 

 https://news.abbvie.com/news/press-releases/abbvie-receives-positive-chmp-opinion-for-maviret-glecaprevirpibrentasvir-to-shorten-treatment-duration-to-eight-weeks-in-genotype-3-treatment-nave-patients-with-chronic-hepatitis-c-and-compensated-cirrhosis.htm 

 https://seekingalpha.com/symbol/ABBV 

Fri January 31, 2020 6:55 AM|PR Newswire|About: ABBV

Newswire

NORTH CHICAGO, Ill., Jan. 31, 2020 /PRNewswire/ -- AbbVie (ABBV)

 https://www.abbvie.com/our-science/therapeutic-focus-areas/oncology.html 

 https://www.abbvie.com/ 

 https://news.abbvie.com/news/press-releases/abbvie-receives-positive-chmp-opinion-for-venclyxto-as-chemotherapy-free-combination-regimen-for-patients-with-previously-untreated-chronic-lymphocytic-leukemia.htm 

 https://www.prnewswire.com/news-releases/abbvie-receives-positive-chmp-opinion-for-venclyxto-as-a-chemotherapy-free-combination-regimen-for-patients-with-previously-untreated-chronic-lymphocytic-leukemia-300996798.html 

 https://seekingalpha.com/symbol/ABBV 

Fri January 31, 2020 6:15 AM|PR Newswire|About: LLY 

 https://www.humalog.com/index.aspx 

 https://www.lillyinsulinlispro.com/ 

 https://www.lillydiabetes.com/ 

 https://www.lilly.com/ 

 https://investor.lilly.com/news-releases/news-release-details/chmp-recommends-approval-lillys-new-fast-acting-mealtime-insulin 

 https://www.prnewswire.com/news-releases/chmp-recommends-approval-of-lillys-new-fast-acting-mealtime-insulin-to-improve-glycemic-control-in-adults-with-diabetes-300996785.html 

 On 30 January 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Ruxience, intended for the treatment of non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukaemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), and Pemphigus vulgaris (PV). The applicant for this medicinal product is Pfizer Europe MA EEIG. 

Jan. 31, 2020 7:47 AM ET|About: Pfizer Inc. (PFE)|By: Douglas W. House, SA News Editor 

 https://seekingalpha.com/news/3536804-european-advisory-group-backs-pfizers-rituxan-biosimilar 

 https://seekingalpha.com/symbol/PFE 

Thu January 30, 2020 6:15 AM|PR Newswire|About: INCY, LLY

PR Newswire

INDIANAPOLIS, Jan. 30, 2020 /PRNewswire/ -- Eli Lilly and Company (LLY)

 http://pi.lilly.com/us/olumiant-uspi.pdf 

 https://www.lilly.com/ 

 https://investor.lilly.com/news-releases/news-release-details/lilly-and-incyte-announce-positive-top-line-results-north 

 https://www.incyte.com/ 

 https://www.prnewswire.com/news-releases/lilly-and-incyte-announce-positive-top-line-results-from-the-north-american-breeze-ad5-phase-3-study-of-oral-selective-jak-inhibitor-baricitinib-in-patients-with-moderate-to-severe-atopic-dermatitis-300995759.html 

 https://seekingalpha.com/symbol/INCY 

 https://seekingalpha.com/symbol/LLY 

Jan. 30, 2020 7:16 AM ET|About: Bayer Aktiengesellschaft (BAYRY)|By: Douglas W. House, SA News Editor  

  Nubeqa 

 https://clinicaltrials.gov/ct2/show/NCT02200614?titles=aramis&lead=bayer&phase=2&draw=2&rank=1 

 https://media.bayer.com/baynews/baynews.nsf/id/en-doccheck-disclaimer?OpenDocument&dcp=Darolutamide-androgen-deprivation-therapy-significantly-increased-overall-survival-non-metastatic&pi=2020-0026&ccm= 

 https://seekingalpha.com/symbol/BAYRY 

Thu January 30, 2020 1:00 AM|GlobeNewswire|About: SNY

Positive topline results demonstrated by olipudase alfa, first and only investigational therapy in late-stage development for acid sphingomyelinase deficiency

                 · Acid sphingomyelinase deficiency (ASMD) is a rare, progressive and potentially life-threatening disease for which no treatments are approved

PARIS – January 30, 2020 – 

i www.clinicaltrials.gov; ClinicalTrials.gov Identifier: NCT02004691

ii www.clinicaltrials.gov; ClinicalTrials.gov Identifier: NCT02292654

 https://www.sanofi.com/en/media-room/press-releases/2020/2020-01-30-07-00-00 

 https://seekingalpha.com/symbol/SNY 

Thu January 30, 2020 9:00 AM|PR Newswire|About: ABT

PR Newswire

ABBOTT PARK, Ill., Jan. 30, 2020 /PRNewswire/ -- Abbott (ABT)

 MITRACLIP CLIP DELIVERY SYSTEMS
INDICATION FOR USE 

 https://www.structuralheartsolutions.com/us/structural-heart-products-solutions/mitral-valve-mitraclip/overview/#isi 

 https://www.abbott.com/ 

 https://www.prnewswire.com/news-releases/abbotts-tendyne-device-receives-worlds-first-ce-mark-for-transcatheter-mitral-valve-implantation-300995780.html 

 https://seekingalpha.com/symbol/ABT 

Thu January 30, 2020 9:30 AM|GlobeNewswire|About: MDT

Next Generation Technology Includes Features that Automatically Adjust to Patient Needs, and Offers Physicians Heart Failure Diagnostic Insights

DUBLIN, Jan. 30, 2020 (GLOBE NEWSWIRE) --  Medtronic plc (MDT)

 https://www.medtronic.com/us-en/index.html 

 https://www.medtronic.com/us-en/healthcare-professionals/reimbursement/cardiac-rhythm-heart-failure/resources-device-type/implantable-cardioverter-defibrillators.html 

 https://seekingalpha.com/symbol/MDT 

Thu January 30, 2020 7:05 AM|Business Wire|About: BMY

Boehringer Ingelheim initiates Phase 1 clinical trial for SOS1:KRAS inhibitor BI 1701963, a FORMA-discovered, BI-licensed protein-protein interaction program for patients with advanced, KRAS-mutated solid tumors

Bristol-Myers Squibb (BMY) initiates Phase 1B clinical trial in patients with advanced or unresectable solid tumors for FORMA-discovered, Celgene-licensed pan BET inhibitor CC-95775

WATERTOWN, Mass.--(BUSINESS WIRE)-- FORMA Therapeutics, Inc., a clinical stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the achievement of clinical development milestones for two of its exclusively-licensed, clinical-stage products to Boehringer Ingelheim (BI) and Bristol-Myers Squibb Company (BMS) (NYSE:BMY).

BI initiated a Phase 1 clinical trial for BI 1701963, a SOS1:KRAS inhibitor

 https://www.boehringer-ingelheim.com/human-pharma/innovation-disease-focus/beginning-end-kras-cancers 

 https://www.businesswire.com/news/home/20200130005064/en/ 

 https://www.formatherapeutics.com/pipeline/ 

 https://seekingalpha.com/symbol/BMY 

Wed January 29, 2020 6:45 AM|PR Newswire|About: LLY

INDIANAPOLIS, Jan. 29, 2020 /PRNewswire/ -- Eli Lilly and Company (LLY)

 https://www.lillyoncology.com/ 

 https://www.lilly.com/ 

 https://www.prnewswire.com/news-releases/lilly-receives-fda-priority-review-for-the-selpercatinib-new-drug-application-300995006.html 

 https://seekingalpha.com/symbol/LLY 

Wed January 29, 2020 2:01 AM|Business Wire|About: EXEL

– Submission based on two clinical trials in patients with advanced hepatocellular carcinoma who had received prior systemic therapy –

ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (EXEL) (NASDAQ: EXEL) today announced that Takeda Pharmaceutical Company Limited (Takeda (TKPHF))

 https://cabometyx.com/downloads/CABOMETYXUSPI.pdf 

 https://www.exelixis.com/ 

 https://www.businesswire.com/news/home/20200128005841/en/ 

 https://seekingalpha.com/symbol/TKPHF 

 https://seekingalpha.com/symbol/EXEL 

 https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-partner-takeda-files-new-drug-application 

Wed January 29, 2020 7:00 AM|GlobeNewswire|About: SRNE

SAN DIEGO and WARREN, N.J., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (SRNE) 

 https://sorrentotherapeutics.com/ 

 https://www.celularity.com/ 

 https://seekingalpha.com/symbol/SRNE 

 https://www.janssen.com/  

Wed January 29, 2020 8:48 AM|PR Newswire|About: JNJ 

 J&J enters coronavirus fray with planned vaccine

Jan. 29, 2020 9:11 AM ET|About: Johnson & Johnson (JNJ)|By: Douglas W. House, SA News Edito 

 https://seekingalpha.com/news/3535736-j-and-j-enters-coronavirus-fray-planned-vaccine 

 The vaccine program will leverage Janssen's AdVac® and PER.C6® technologies 

 (JNJ)   has also donated 300 boxes of HIV med Prezcobix (darunavir/cobicistat) to the Shanghai Public Health Clinical Center and Zhongnan Hospital of Wuhan University for use in research to support efforts in finding a solution against 2019-nCoV. An additional 50 boxes have been provided to the Chinese Center for Disease Control and Prevention for laboratory-based investigations (drug-screening for antiviral properties against 2019-nCoV). 

 https://www.janssen.com/ 

 https://www.prnewswire.com/news-releases/johnson--johnson-launches-multi-pronged-response-to-coronavirus-global-public-health-threat-300995266.html 

The coronavirus has made headlines as it has spread from China to other parts of the world. To help stop the global outbreak in its tracks, Johnson & Johnson is already hard at work on a potential preventive vaccine.By Johnson & JohnsonJanuary 28, 2020 

 https://www.jnj.com/latest-news/what-you-need-to-know-about-coronavirus-and-a-potential-johnson-johnson-vaccine 

Wed January 29, 2020 8:00 AM|GlobeNewswire|About: ICPT

NEW YORK, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (ICPT)

 https://www.interceptpharma.com/ 

 https://seekingalpha.com/symbol/ICPT 

Our four current technologies are designed to stimulate and enhance the immune system.

Jan. 27, 2020 10:19 AM ET|About: Vir Biotechnology, Inc. (VIR)|By: Douglas W. House, SA News Editor  platforms

Our four current technologies are designed to stimulate and enhance the immune system.

 (VIR)   has four technology platforms that it is leveraging to develop treatments for infectious diseases, including influenza and tuberculosis. 

 https://seekingalpha.com/symbol/VIR 

 https://www.vir.bio/ 

Tue January 28, 2020 4:15 PM|Business Wire|About: GILD

-- Investigational KTE-X19 To Be First Chimeric Antigen Receptor (CAR) T Cell Therapy for Mantle Cell Lymphoma in Europe if Approved --

-- Filing for Kite’s Second CAR T Therapy Marks Potential Expansion of Company’s Cell Therapy Portfolio --

SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite, a Gilead Company (Nasdaq: GILD)

 https://www.kitepharma.com/ 

 https://www.gilead.com/ 

 https://www.businesswire.com/news/home/20200128005723/en/ 

 https://seekingalpha.com/symbol/GILD 

January 23, 2020

Pfizer will become the first company to bring three oncology monoclonal antibody (mAb) biosimilar treatments to the U.S. market

Pfizer announced that it is introducing three new biosimilars, ZIRABEV™ (bevacizumab-bvzr), RUXIENCE™ (rituximab-pvvr) and TRAZIMERA™ (trastuzumab-qyyp) in the United States (U.S.). The medicines are expected to launch at the lowest Wholesale Acquisition Cost (WAC) among bevacizumab, rituximab or trastuzumab products currently on the market, becoming available at a substantially discounted price to the originator product.

 https://www.pfizer.com/ 

1 Avastin® is a registered trademark of Genentech, Inc.

2 Rituxan® is a registered trademark of Genentech, Inc. and Biogen, Inc.

3 Herceptin® is a registered trademark of Genentech, Inc.

 https://clinicaltrials.gov/ct2/show/NCT02031991?term=reflections%2Bbevacizumab 

 https://clinicaltrials.gov/ct2/show/NCT01989676?term=NCT01989676 

 https://clinicaltrials.gov/ct2/show/NCT02187744?term=NCT02187744 

 https://seekingalpha.com/symbol/PFE 

Tue January 28, 2020 7:00 AM|PR Newswire|About: BHC, CLSD

LAVAL, Quebec and ALPHARETTA, Ga., Jan. 28, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (BHC) ("Bausch Health") and Bausch + Lomb, its leading global eye health business, and Clearside Biomedical (CLSD), Inc. (Nasdaq: CLSD)

 http://www.clearsidebio.com/ 

 https://www.bausch.com/ 

 https://www.prnewswire.com/news-releases/bausch-health-and-clearside-biomedical-announce-publication-of-pivotal-phase-3-data-on-xiperetm-triamcinolone-acetonide-suprachoroidal-injectable-suspension-in-ophthalmology-300994122.html 

 https://seekingalpha.com/symbol/BHC 

 https://seekingalpha.com/symbol/CLSD 

Tue January 28, 2020 4:05 PM|Business Wire|About: TEVA

PARSIPPANY, N.J.--(BUSINESS WIRE)-- Teva Pharmaceuticals USA, Inc. an affiliate of Teva Pharmaceutical Industries Ltd. (TEVVF) (NYSE and TASE: TEVA)

 https://www.tevapharm.com/ 

 https://www.businesswire.com/news/home/20200128005810/en/ 

 https://seekingalpha.com/symbol/TEVA 

Tue January 28, 2020 4:05 PM|GlobeNewswire|About: AKCA, IONS

Favorable safety and tolerability were observed

Primary and multiple secondary endpoints were met with significant reduction in triglyceride levels, additional lipid parameters and ANGPTL3

BOSTON and CARLSBAD, Calif., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (IONS), and Ionis Pharmaceuticals, Inc.,

 https://akceatx.com/ 

 https://www.ionispharma.com/ 

 https://akceatx.com/our-programs/pipeline/ 

 https://seekingalpha.com/symbol/IONS 

 https://seekingalpha.com/symbol/AKCA 

• There are 840 newly confirmed cases in Hubei province, where the outbreak began, Chinese health authorities say
• Most patients who have died were older than 60 and had pre-existing conditions, according to local authorities

Cissy Zhou andWilliam Zheng

Published: 7:08am, 29 Jan, 2020

 https://www.caixinglobal.com/ 

 Jan 29, 2020 06:25 AMSOCIETY & CULTURE

By Wen Simin, Zhao Zuoyan and Denise Jia 

 https://www.caixinglobal.com/2020-01-29/hong-kong-sharply-cuts-transport-links-with-mainland-in-virus-fight-101509187.html 

 China coronavirus: Washington asks Beijing for permission to send health team to battle outbreak

• Health and Human Services Secretary Alex Azar says he hopes ‘the Chinese government will take us up’ on the offer
• Centres for Disease Control and Prevention director says agency seeks data concerning the transmission of the disease

Robert Delaney

Published: 2:04am, 29 Jan, 2020

 https://www.scmp.com/news/china/article/3047967/china-coronavirus-washington-asks-beijing-permission-send-health-team 

 Wuhan Virus  

Source: China's NHC, state media, other authorities

SCMP

 https://multimedia.scmp.com/widgets/china/wuhanvirus/# 

Español 

 https://www.cdc.gov/flu/season/faq-flu-season-2019-2020.htm 

Tue January 28, 2020 12:59 AM|PR Newswire|About: REGN

TARRYTOWN, N.Y. and PARIS, Jan. 28, 2020 /PRNewswire/ --

If approved, Dupixent would be the first biologic medicine available in the U.S. for these children

Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi 

 https://www.regeneron.com/sites/default/files/Dupixent_FPI.pdf 

 https://www.regeneron.com/ 

 https://investor.regeneron.com/news-releases/news-release-details/fda-accepts-priority-review-dupixentr-dupilumab-children-aged-6 

 https://www.prnewswire.com/news-releases/fda-accepts-for-priority-review-dupixent-dupilumab-for-children-aged-6-to-11-years-with-moderate-to-severe-atopic-dermatitis-300994046.html 

 https://seekingalpha.com/symbol/REGN 

  Trijardy combines three medicines - Jardiance (empagliflozin), Tradjenta (linagliptin) and metformin hydrochloride extended release - in one pill, which will be a once-a-day medication. 

Mon January 27, 2020 5:34 PM|PR Newswire|About: LLYPR Newswire

RIDGEFIELD, Conn., and INDIANAPOLIS, Jan. 27, 2020 /PRNewswire/

 https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Trijardy%20XR/Trijardy%20XR.pdf?DMW_FORMAT=pdf 

 https://www.boehringer-ingelheim.us/our-responsibility/our-responsibility 

 https://www.lillydiabetes.com/ 

 https://www.prnewswire.com/news-releases/us-fda-approves-only-triple-combination-tablet-with-jardiance-for-adults-with-type-2-diabetes-300993928.html 

 https://www.lilly.com/ 

TRADJENTA is a prescription medicine that is used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.

TRADJENTA is not for people with type 1 diabetes or for people with diabetic ketoacidosis (increased ketones in the blood or urine).

If you have had inflammation of the pancreas (pancreatitis) in the past, it is not known if you have a higher chance of getting pancreatitis while you take TRADJENTA.

 https://www.tradjenta.com/ 

 JARDIANCE is the first type 2 diabetes pill proven to go beyond lowering A1C to reduce the risk of cardiovascular (CV) death for adults who have type 2 diabetes and known heart disease. 

 https://www.jardiance.com/ 

Tue January 28, 2020 7:00 AM|PR Newswire|About: ALKS

DUBLIN, Jan. 28, 2020 /PRNewswire/ -- Alkermes plc (ALKS) (Nasdaq: ALKS)

 http://www.alkermes.com/ 

 https://www.prnewswire.com/news-releases/alkermes-announces-us-food-and-drug-administration-acceptance-of-alks-3831-new-drug-application-for-treatment-of-schizophrenia-and-bipolar-i-disorder-300994014.html 

 https://seekingalpha.com/symbol/ALKS 

Tue January 28, 2020 6:30 AM|GlobeNewswire|About: MRK

Safety and early efficacy data to be presented from clinical trial of Bria-IMT™ in combination with immune checkpoint inhibitors in advanced breast cancer:
• Bria-IMT™ in combination with pembrolizumab (KEYTRUDA®; by Merck & Co., Inc. (MRK));
• Bria-IMT™ in combination with INCMGA00012 (by Incyte Corporation).

BERKELEY, Calif., and VANCOUVER, British Columbia, Jan. 28, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (BCTXF) ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXD)

 https://briacell.com/novel-technology/scientific-publications/ 

  ClinicalTrials.gov as NCT03328026. 

 https://briacell.com/ 

 http://www.cancerinsight.com/ 

 https://seekingalpha.com/symbol/BCTXF 

Tue January 28, 2020 6:30 AM|Canada Newswire|About: AMRN, HLTRF

• Vascepa to be available on or about February 18, 2020, supported by a national Cardiovascular salesforce
• Vascepa becomes the first and only Health Canada-approved medication for reducing cardiovascular risk beyond cholesterol-lowering therapy in the studied high-risk patients approved for treatment
• Vascepa is supported by data from the REDUCE-IT® trial, an international 8,179 patient outcomes study that showed a 25% placebo-controlled risk reduction in the first occurrence of major adverse cardiovascular events
• Cardiovascular disease is the number one killer globally1 and HLS is taking steps to make Vascepa accessible and affordable to the Canadian population

TORONTO, Jan. 28, 2020 /CNW/ - HLS Therapeutics Inc. (HLTRF) ("HLS" or the "Company") (TSX:HLS),

 http://www.hlstherapeutics.com/ 

 https://www.vascepa.com/ 

Jan. 28, 2020 6:55 AM ET|About: HLS Therapeutics Inc. (HLTRF)|By: Douglas W. House, SA News Editor 

 https://seekingalpha.com/news/3535025-vascepa-to-launch-in-canada-next-month 

 https://seekingalpha.com/symbol/HLTRF 

 https://seekingalpha.com/symbol/AMRN 

Tue January 28, 2020 7:30 AM|Business Wire|About: INCY

WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (INCY)

 https://clinicaltrials.gov/ct2/show/NCT03745651 

 https://clinicaltrials.gov/ct2/show/NCT03745638 

 https://www.incyte.com/ 

 https://www.businesswire.com/news/home/20200128005173/en/ 

 https://investor.incyte.com/news-releases/news-release-details/incyte-announces-true-ad2-pivotal-trial-ruxolitinib-cream-met 

 https://seekingalpha.com/symbol/INCY 

Mon January 27, 2020 6:45 AM|Business Wire|About: MRK

KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (MRK)

 https://www.businesswire.com/news/home/20200127005296/en/ 

 https://www.merck.com/index.html 

 https://www.merckconnect.com/dificid/coverage/ 

 https://www.mrknewsroom.com/news-release/prescription-medicine-news/fda-approves-mercks-dificid-fidaxomicin-treat-clostridioides 

Mon January 27, 2020 7:00 AM|Business Wire|About: AZN

BRILINTA reduced the risk of the composite of stroke and death after an acute ischemic stroke or transient ischemic attack

WILMINGTON, Del.--(BUSINESS WIRE)-

 https://www.azpicentral.com/brilinta/brilinta.pdf#page=1 

 https://www.businesswire.com/news/home/20200127005174/en/ 

 https://www.astrazeneca-us.com/ 

 https://www.astrazeneca-us.com/content/az-us/media/press-releases/2020/brilinta-met-primary-endpoint-in-the-phase-iii-thales-trial-in-stroke-01272020.html 

 https://www.brilinta.com/#isihead 

Jan. 27, 2020 7:28 AM ET|About: AstraZeneca PLC (AZN)|By: Douglas W. House, SA News Editor  

 https://seekingalpha.com/news/3534593-astrazenecas-brilinta-reduced-risk-of-stroke-death-in-late-stage-study 

Mon January 27, 2020 6:45 AM|PR Newswire|About: INCY, LLY

PR Newswire

INDIANAPOLIS, Jan. 24, 2020 /PRNewswire/ -- Eli Lilly and Company (LLY) and Incyte (INCY) 

 http://pi.lilly.com/us/olumiant-uspi.pdf 

 https://www.lilly.com/ 

 https://www.incyte.com/ 

 https://www.prnewswire.com/news-releases/lilly-and-incyte-announce-top-line-results-from-phase-3-study-breeze-ad4-of-oral-selective-jak-inhibitor-baricitinib-in-combination-with-topical-corticosteroids-in-patients-with-moderate-to-severe-atopic-dermatitis-not-controlle-300993285.html 

Mon January 27, 2020 1:00 AM|Business Wire|About: RHHBY

– Application is being reviewed under FDA's Real-Time Oncology Review pilot program –

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY)

 https://www.gene.com/topics/cancer-immunotherapy 

 https://www.gene.com/ 

 https://www.businesswire.com/news/home/20200126005034/en/ 

 https://www.gene.com/media/press-releases/14835/2020-01-26/genentech-submits-supplemental-biologics 

 https://www.avastin.com/ 

 https://www.tecentriq.com/ 

Mon January 27, 2020 7:31 AM|Canada Newswire

In the Phase 3 pivotal trial, nearly 44 per cent of patients receiving STELARA® subcutaneous (SC) injections every 8 weeks were in clinical remission at one year

TORONTO, Jan. 27, 2020 /CNW/ - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that Health Canada has approved STELARA® (ustekinumab) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC)

 https://www.nejm.org/doi/10.1056/NEJMoa1900750 

 https://www.janssen.com/canada/ 

 https://www.jnj.com/ 

Mon January 27, 2020 2:00 AM|Business Wire|About: DSNKY

• Trial met primary endpoint of objective response rate and key secondary endpoint of overall survival in patients with previously treated HER2 positive metastatic gastric cancer

TOKYO, MUNICH & BASKING RIDGE, N.J.--(BUSINESS WIRE)-- Daiichi Sankyo Company, Limited (DSKYF) (hereafter, Daiichi Sankyo (DSKYY)) and AstraZeneca 

 https://dsi.com/oncology 

 https://www.daiichisankyo.com/ 

 https://www.businesswire.com/news/home/20200126005029/en/ 

Jan. 27, 2020 11:29 AM ET|About: Daiichi Sankyo Company... (DSKYF)|By: Douglas W. House, SA News Editor 

 https://seekingalpha.com/news/3534766-daiichi-astrazeneca-adc-successful-in-mid-stage-gastric-cancer-study 

 https://clinicaltrials.gov/ct2/show/NCT03329690?term=destiny-gastric01&draw=2&rank=1 

Thu January 23, 2020 7:00 AM|PR Newswire|About: LPTX

PR Newswire

CAMBRIDGE, Mass., Jan. 23, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (LPTX)

 https://www.prnewswire.com/news-releases/leap-therapeutics-presents-updated-data-at-the-asco-2020-gastrointestinal-cancers-symposium-asco-gi-global-meeting-300991794.html 

 https://www.leaptx.com/ 

 https://investors.leaptx.com/news-releases/news-release-details/leap-therapeutics-presents-updated-data-asco-2020 

Jan. 23, 2020 7:48 AM ET|About: Leap Therapeutics, Inc. (LPTX)|By: Douglas W. House, SA News Editor 

 https://seekingalpha.com/news/3533853-leaps-dknminus-01-shows-positive-effect-in-esophagogastric-cancer 

Thu January 23, 2020 10:00 AM|GlobeNewswire|About: MDT

Investigative Technology Designed to Interrupt Irregular Pathways in the Heart

DUBLIN, Jan. 23, 2020 (GLOBE NEWSWIRE) --  Medtronic plc (MDT)

 https://www.medtronic.com/us-en/index.html 

The Emprint™ ablation system maintains predictable spherical ablation zones throughout procedures.

 https://www.medtronic.com/covidien/en-us/products/ablation-systems/emprint-ablation-system.html 

Jan. 23, 2020 10:27 AM ET|About: Medtronic plc (MDT)|By: Douglas W. House, SA News Editor  

 https://seekingalpha.com/news/3533983-fda-signs-off-on-study-of-medtronic-pfa-system-for-atrial-fibrillation 

• The Hebei victim, aged 80, was visiting relatives in Wuhan before he was diagnosed; 76 people who had close contact with him have reportedly been quarantined
• Travel bans have been imposed on eight cities in Hubei province: Wuhan, Huanggang, Ezhou, Chibi, Xiantao, Qianjiang, Zhijiang and Lichuan

Cissy Zhou andRobert Delaney in Washington

Published: 2:05am, 24 Jan, 2020

Source: Xinhua| 2020-01-23 21:53:15|Editor: huaxia 

 http://www.xinhuanet.com/english/2020-01/23/c_138729811.htm 

Source: Xinhua| 2020-01-23 21:26:12|Editor: huaxia 

 http://www.xinhuanet.com/english/2020-01/23/c_138729715.htm 

Fri January 24, 2020 7:30 AM|Business Wire|About: EXEL

– Data from the CheckMate 040 trial presented at the 2020 American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium –

ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (EXEL)

 https://www.exelixis.com/ 

 https://clinicaltrials.gov/ct2/show/NCT01658878?term=NCT01658878 

 https://www.businesswire.com/news/home/20200124005066/en/ 

 https://www.cabometyx.com/ 

 https://seekingalpha.com/symbol/EXEL 

BLOOMBERG

• JAN 26, 2020ARTICLE HISTORY

BEIJING – China is using AbbVie Inc.’s HIV drugs as an ad-hoc treatment for pneumonia caused by the novel coronavirus while the global search for a cure continues.

World
China Names AbbVie’s HIV Drugs in Treatment Plan for New Virus

 https://www.bloomberg.com/news/articles/2020-01-26/china-names-abbvie-s-hiv-drugs-in-treatment-plan-for-new-virus 

AbbVie Drugs Named as Part of China Treatment Plan: Virus Update

 https://www.bloomberg.com/news/articles/2020-01-25/wuhan-gets-aid-as-singapore-malaysia-report-cases-virus-update 

 https://www.scmp.com/news/china/society/article/3047720/chinese-premier-li-keqiang-head-coronavirus-crisis-team-outbreak 

 https://www.abbvie.com/our-science/products.html 

 https://www.theguardian.com/science/2020/jan/25/scientists-race-to-find-out-how-wuhan-victims-became-ill-coronavirus 

 https://www.nytimes.com/2020/01/25/world/asia/china-coronavirus.html 

 https://www.caixinglobal.com/ 

Wuhan Coronavirus map (with updates)

 https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6 

 Wuhan Virus 

 https://multimedia.scmp.com/widgets/china/wuhanvirus/# 

• One woman said her husband had been feverish and coughing blood but was turned away by several hospitals that said they had no room
• Desperate scenes come as death toll rises to 41 and more than 1,000 cases of infection confirmed nationwide

Mimi Lau

Published: 7:00am, 25 Jan, 2020

• Deaths in Hubei province, the epidemic’s epicentre, rise by 15 as contagion spreads
• Some 29 Chinese provinces have reported 1,112 cases of the deadly pneumonia-like virus

Cissy Zhou

Published: 7:35am, 25 Jan, 2020

 https://www.scmp.com/news/china/society/article/3047631/china-coronavirus-death-toll-rises-41-over-1000-cases-infection 

 Jan 24, 2020 06:43 PMSOCIETY & CULTURE

By Matthew Walsh, Flynn Murphy, Han Wei and Lin Jinbing 

 https://www.caixinglobal.com/2020-01-24/wuhan-virus-latest-china-reports-second-pneumonia-linked-death-101505300.html 

Source: Xinhua| 2020-01-25 09:14:13|Editor: Lu Hui 

 http://www.xinhuanet.com/english/2020-01/25/c_138732461.htm 

 https://www.caixinglobal.com/ 

 Jan 25, 2020 12:46 AMSOCIETY & CULTURE

By Dave Yin 

 https://www.caixinglobal.com/2020-01-25/months-needed-to-develop-coronavirus-vaccine-epidemiology-group-101508197.html 

Thu January 23, 2020 8:00 AM|GlobeNewswire|About: LLYGlobeNewswire

TORONTO, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Eli Lilly Canada

 https://www.lilly.ca/en/index.aspx 

 https://www.diabetes.ca/health-care-providers/clinical-practice-guidelines/chapter-14#panel-tab_FullText 

 https://www.baqsimi.ca/ 

 https://www.baqsimi.com/ 

Thu January 23, 2020 7:31 AM|Canada Newswire|About: MRK

Approval Based on Results of KEYNOTE-426, Where KEYTRUDA® in Combination with Axitinib Reduced the Risk of Death by Nearly Half Compared to Sunitinib

• Renal cell carcinoma (RCC) is the most common form of kidney cancer, representing 80 per cent of all cases1
• The five-year survival rate for advanced RCC is currently estimated to be 8 per cent2

KIRKLAND, QC, Jan. 23, 2020 /CNW/ - Merck (MRK)

 https://www.merck.ca/en/home/ 

 https://www.merck.ca/static/pdf/KEYTRUDA-PM_E.pdf 

 https://www.inlyta.com/ 

 https://www.keytruda.com/ 

Thu January 23, 2020 6:45 AM|Business Wire|About: PFE

Agreement provides Roman members with erectile dysfunction treatment backed by Pfizer’s quality manufacturing standards and supply chain excellence

PEAPACK, N.J. & NEW YORK--(BUSINESS WIRE)-- Greenstone, Upjohn’s U.S.-based generics business and a wholly owned subsidiary of Pfizer Inc. (PFE)

 https://www.greenstonellc.com/products 

 https://www.greenstonegenerics.com/ 

 https://www.pfizer.com/ 

 https://www.businesswire.com/news/home/20200123005195/en/ 

Thu January 23, 2020 8:30 AM|GlobeNewswire|About: MDT

 Efficio Software Provides Enhanced, Secure Access to Patient Data and Delivers
Actionable Insights in a Secure Cloud Environment

DUBLIN, Jan. 23, 2020 (GLOBE NEWSWIRE) --  Medtronic plc (MDT)

 https://www.medtronic.com/us-en/c/efficio.html?cmpid=vanity_url_medtronic_com_Efficio_RTG_Pain_FY20 

 https://www.medtronic.com/us-en/index.html 

 http://newsroom.medtronic.com/news-releases/news-release-details/medtronic-launches-efficiotm-software-help-clinicians 

Thu January 23, 2020 9:15 AM|Business Wire|About: AZN, MRK, MRNA

Collaboration includes the National Institutes of Health (NIH) and leverages flexibility of Moderna’s mRNA vaccine technology

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Moderna, Inc. (MRNA), (Nasdaq: MRNA)

 https://seekingalpha.com/symbol/MRNA 

 https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-additional-positive-phase-1-data 

 https://investors.modernatx.com/news-releases/news-release-details/moderna-receives-fda-fast-track-designation-zika-vaccine-mrna 

 https://www.modernatx.com/ 

 https://www.modernatx.com/pipeline/therapeutic-areas/infectious-diseases 

Jan. 23, 2020 9:41 AM ET|About: Moderna, Inc. (MRNA)|By: Douglas W. House, SA News Editor  

 https://seekingalpha.com/news/3533957-moderna-nabs-funding-to-make-vaccine-against-china-coronavirus 

 China / Society

• Almost half the fatalities were 80 years or older, all of them from Hubei province
• Chinese authorities say children have been infected but are not highly susceptible to the virus

Keegan Elmer andLaurie Chen

Published: 8:30pm, 23 Jan, 2020

By Nathaniel TaplinUpdated Jan. 23, 2020 5:05 am ET

 https://www.wsj.com/articles/wuhan-coronavirus-could-hit-chinas-economy-harder-than-sars-11579773756?mod=pls_whats_news_us_business_f 

Jan. 23, 2020 6:59 AM ET|About: Moderna, Inc. (MRNA)|By: Douglas W. House, SA News Editor  

 https://seekingalpha.com/news/3533816-respiratory-virus-in-china-less-virulent-2003-sars 

Tue January 21, 2020 12:47 PM|PR Newswire|About: LLYPR Newswire

RALEIGH, N.C., Jan. 21, 2020 /PRNewswire/ -- Eli Lilly and Company (LLY)

 https://www.nccommerce.com/grants-incentives/county-distress-rankings-tiers 

 https://www.lilly.com/ 

 https://www.prnewswire.com/news-releases/governor-cooper-announces-over-460-jobs-in-durham-as-eli-lilly-and-company-selects-north-carolina-for-major-pharmaceutical-plant-300990502.html 

Jan. 21, 2020 1:21 PM ET|About: Eli Lilly and Company (LLY)|By: Douglas W. House, SA News Editor  

 https://seekingalpha.com/news/3533180-lilly-to-invest-470m-in-north-carolina-site 

Tue January 21, 2020 3:04 PM|Business Wire|About: HZNP

-- First and only FDA-approved medicine for TED, a serious, progressive, vision-threatening rare disease --

-- Clinical improvements were seen as early as six weeks, with continued improvement across the 24-week treatment period --

-- Approval comes ahead of the Prescription Drug User Fee Act (PDUFA) goal date of March 8, 2020 --

-- Horizon to host investor webcast Tuesday, January 21 at 5:00 p.m. ET --

DUBLIN--(BUSINESS WIRE)-- Horizon Therapeutics plc (Nasdaq: HZNP)

 https://www.nejm.org/doi/full/10.1056/NEJMoa1614949 

 https://ir.horizontherapeutics.com/ 

 https://www.horizontherapeutics.com/ 

 https://www.horizontherapeutics.com/our-pipeline/ 

 https://www.businesswire.com/news/home/20200121006017/en/ 

 https://seekingalpha.com/symbol/HZNP 

Tue January 21, 2020 6:07 PM|GlobeNewswire|About: MDT

At Three-Months, 80% of Patients Treated with DTM SCS Reported Back Pain Relief
of at Least 50%; 63% Reported Profound Back Pain Relief of 80% or Greater1

DUBLIN, Jan. 21, 2020 (GLOBE NEWSWIRE) --  Medtronic plc (MDT) 

 https://www.medtronic.com/us-en/index.html 

 The Intellis™ with AdaptiveStim™ implantable neurostimulator is powered by proprietary Overdrive™ battery technology. It is designed to overcome limitations with other SCS systems and is optimized for the increased energy demands of High Dose (HD) therapy. Medtronic exclusive features on the Intellis™ platform include wireless programming using the clinician tablet, wireless trialing system, and SureScan™ full-body MRI technologies. 

 https://www.medtronic.com/us-en/healthcare-professionals/products/neurological/spinal-cord-stimulation-systems/intellis-platform.html 

• Risdiplam demonstrated statistically significant and medically meaningful motor milestone improvement in infants with Type 1 SMA
• No treatment related safety findings leading to withdrawal seen in any risdiplam trial to date
• Data will be shared with health authorities globally

Basel, 23 January 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY)

Jan. 23, 2020 6:42 AM ET|About: Roche Holding AG (RHHBY)|By: Douglas W. House, SA News Editor  

 https://seekingalpha.com/news/3533806-roches-risdiplam-successful-in-sma-study 

 https://seekingalpha.com/pr/17756953-genentech-s-risdiplam-meets-primary-endpoint-in-pivotal-firefish-trial-in-infants-type-1 

Wed January 22, 2020 7:00 AM|GlobeNewswire|About: AXSM

NEW YORK, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (AXSM),

 https://axsome.com/ 

 https://axsome.com/axs-pipeline/overview/ 

 https://seekingalpha.com/symbol/AXSM 

 Hong Kong / Health & Environment

• Professor Yuen Kwok-yung, a top infectious diseases expert, says transmission of new coronavirus has entered its ‘third wave’
• Warning comes as Hong Kong University study suggests outbreak worse than officially reported, with virus already spreading to 20 mainland cities

Elizabeth Cheung

Published: 6:17pm, 21 Jan, 2020

Jan 20, 2020

• Mayzent® (siponimod) is the first and only oral treatment specifically indicated for patients with secondary progressive multiple sclerosis (SPMS) with active disease in Europe1
   
• Mayzent addresses an unmet need for SPMS patients with active disease who, until now, did not have an oral treatment that has been shown to be effective in delaying progression in this patient population
   
• Approval is based on the Phase III EXPAND trial, the largest randomized clinical study in a broad range of SPMS patients, showing Mayzent significantly reduced the risk of disease progression, including physical disability and cognitive decline2,3
•  Basel, January 20, 2020 

 https://www.pharmaceutical-technology.com/news/eu-approval-novartis-mayzent/ 

Jan. 21, 2020 6:49 AM ET|About: Novartis AG (NVS)|By: Douglas W. House, SA News Editor  

 https://seekingalpha.com/news/3532960-novartis-mayzent-okd-in-europe-for-multiple-sclerosis 

 https://www.mayzent.com/index.jsp 

Basel, 21 January 2020

• Novel combination regimen includes first-in-class antibody-drug conjugate that specifically targets CD79b
• Targeted off-the-shelf treatment provides much-needed new option for people with relapsed or refractory diffuse large B-cell lymphoma
• Polivy approval is based on a phase Ib/II study, the first and only study showing improved response rates and overall survival in patients with this aggressive lymphoma who are not candidates for a haematopoietic stem cell transplant, compared to a commonly used regimen

Roche (SIX: RO, ROG; OTCQX: RHHBY) 

 https://www.gene.com/patients/medicines/polivy 

 https://www.polivy.com/hcp.html 

 https://seekingalpha.com/news/3532955-roches-polivy-okd-in-europe-for-dlbcl 

Tue January 21, 2020 7:00 AM|GlobeNewswire|About: BGNE

BEIJING, China, and CAMBRIDGE, Mass., Jan. 21, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (BGNE) (NASDAQ: BGNE; HKEX: 06160)

 (NCT 03594747, known as BGB-A317-307) 

 https://www.beigene.com/ 

Jan. 21, 2020 7:31 AM ET|About: BeiGene, Ltd. (BGNE)|By: Douglas W. House, SA News Editor 

 https://seekingalpha.com/news/3532989-beigenes-tislelizumab-successful-in-late-stage-lung-cancer-study 

Tue January 21, 2020 9:00 AM|PR Newswire|About: GSK

• Biologics License Application based on results from the pivotal DREAMM-2 study of immunoconjugate targeting B-cell maturation antigen (BCMA) in heavily pre-treated patient population who was refractory to an immunomodulatory drug and a proteasome inhibitor, and refractory or intolerant to an anti-CD38 antibody
• Belantamab mafodotin has potential to be the first anti-BCMA treatment available to patients

LONDON, Jan. 21, 2020 /PRNewswire/ -- GlaxoSmithKline plc (GSK)

 https://www.gsk.com/ 

 https://www.gsk.com/en-gb/media/press-releases/us-food-and-drug-administration-fda-grants-priority-review-of-belantamab-mafodotin-for-patients-with-relapsed-or-refractory-multiple-myeloma/ 

 https://www.prnewswire.com/news-releases/us-food-and-drug-administration-fda-grants-priority-review-of-belantamab-mafodotin-for-patients-with-relapsed-or-refractory-multiple-myeloma-300990248.html 

Jan. 21, 2020 9:21 AM ET|About: GlaxoSmithKline plc (GSK)|By: Douglas W. House, SA News Editor 

 https://seekingalpha.com/news/3533065-glaxos-balantamab-mafodotin-nabs-accelerated-review-in-u-s-for-mm 

Tue January 21, 2020 7:40 AM|Business Wire|About: NVCR

ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NVCR)

 https://www.novocure.com/ 

 https://www.businesswire.com/news/home/20200121005576/en/ 

 https://seekingalpha.com/symbol/NVCR 

Tue January 21, 2020 12:01 PM|GlobeNewswire|About: MDT

With FDA Approval, More Patients in the U.S. Are Now Candidates for a Leadless Pacing Option

 DUBLIN, Jan. 21, 2020 (GLOBE NEWSWIRE) --  Medtronic plc (MDT) 

 http://electrophysiology.onlinejacc.org/content/6/1/94 

 https://www.medtronic.com/us-en/index.html 

 https://www.medtronic.com/us-en/patients/treatments-therapies/pacemakers/our/micra.html 

 animation of the Micra AV in use 

 https://www.medtronic.com/content/dam/medtronic-com/us-en/newsroom/media-resources/video-gallery/business-unit/cardiac-rhythm-heart-failure-management/medtronic-micra-av-animation.mp4 

Wed January 15, 2020 11:30 AM|PR Newswire

PR Newswire

BERGEN, Norway, Jan. 15, 2020 /PRNewswire/ -- BerGenBio ASA (BRRGF) (OSE: BGBIO) 

 (ClinicalTrials.gov Identifier: NCT03184571) 

 https://www.bergenbio.com/ 

 https://www.prnewswire.com/news-releases/bergenbio-meets-efficacy-endpoint-for-first-stage-of-phase-ii-trial-with-axl-inhibitor-bemcentinib-in-combination-with-keytruda-in-nsclc-patients-progressing-on-immune-checkpoint-inhibitors-300987587.html 

Jan. 15, 2020 11:57 AM ET|About: BerGenBio ASA (BRRGF)|By: Douglas W. House, SA News Editor  

 https://seekingalpha.com/news/3532096-bergenbios-bemcentinib-shows-positive-action-in-mid-stage-lung-cancer-study 

Wed January 15, 2020 4:05 PM|Business Wire|About: TNDM

SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (TNDM)

 https://www.tandemdiabetes.com/products/tandem-device-updater/control-iq 

 https://www.tandemdiabetes.com/products/t-simulator-demo-app 

 https://www.tandemdiabetes.com/ 

 https://www.tandemdiabetes.com/legal/important-safety-information 

 https://www.businesswire.com/news/home/20200115005808/en/ 

 https://seekingalpha.com/symbol/TNDM 

• Authorities find 136 new infections in Wuhan, confirm first cases in other cities – one in Shenzhen and two in Beijing
• World Health Organisation says there could be some limited human-to-human infection

SCMP Reporters

Published: 8:58am, 20 Jan, 2020

PUBLISHED20 January 2020

Jan. 20, 2020 6:03 AM ET|About: AstraZeneca PLC (AZN)|By: Yoel Minkoff, SA News Editor  

. 

Tue January 21, 2020 6:55 AM|Business Wire|About: MRK

Submission Based on PROfound, the First Phase 3 Trial Evaluating a Targeted Treatment in Biomarker-Selected Prostate Cancer Patients

KENILWORTH, N.J.--(BUSINESS WIRE)-- AstraZeneca and Merck (MRK)

 https://www.azpicentral.com/lynparza_tb/lynparza_tb.pdf#page=1 

Jan. 21, 2020 6:39 AM ET|About: AstraZeneca PLC (AZN)|By: Douglas W. House, SA News Editor  

 https://seekingalpha.com/news/3532956-astrazenecas-lynparza-nabs-accelerated-review-in-u-s-for-prostate-cancer 

 https://www.mrknewsroom.com/news-release/oncology/fda-accepts-regulatory-submission-supplemental-new-drug-application-lynparza-0 

 https://www.businesswire.com/news/home/20200121005282/en/ 

• Priority now must be to stop emergence of ‘super-spreader’, with one carrier already infecting more than a dozen medical personnel, specialist says
• Authorities in Wuhan, the epicentre of the coronavirus outbreak, report a third death and more than 130 new cases over the weekend

Gigi Choy andAlice Yan

Published: 9:40pm, 20 Jan, 2020

Thu January 16, 2020 8:00 AM|Canada Newswire

• Cutaneous squamous cell carcinoma (CSCC) is the second most common form of skin cancer accounting for approximately 20% of all skin cancer cases in Canada.1

OAKVILLE, ON, Jan. 16, 2020 /CNW Telbec/ - The Melanoma Network of Canada

 https://www.melanomanetwork.ca/ 

 http://products.sanofi.ca/en/libtayo.pdf 

Thu January 16, 2020 9:00 AM|PR Newswire|About: ARNAPR Newswire

SAN DIEGO, Jan. 16, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) (Nasdaq: ARNA)

 https://www.arenapharm.com/# 

 http://invest.arenapharm.com/news-releases/news-release-details/fda-grants-fast-track-designation-arena-pharmaceuticals-apd418 

 https://www.arenapharm.com/pipeline/apd418/ 

 https://www.prnewswire.com/news-releases/fda-grants-fast-track-designation-to-arena-pharmaceuticals-apd418-for-development-in-decompensated-heart-failure-patients-300988176.html 

 https://seekingalpha.com/symbol/ARNA 

Mon January 13, 2020 2:25 AM|Accesswire|About: MOR

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / January 13, 2020 / MorphoSys AG (MPSYF) (FSE: MOR;

 https://www.morphosys.com/ 

 https://www.incyte.com/ 

 https://www.accesswire.com/572835/MorphoSys-AG-Ad-hoc-MorphoSys-and-Incyte-Sign-Global-Collaboration-and-License-Agreement-including-US-Co-Commercialization-and-Ex-US-Commercialization-Rights-for-Tafasitamab 

 https://seekingalpha.com/symbol/MOR 

PLAINSBORO, N.J., Jan. 16, 2020 /PRNewswire/ -- Novo Nordisk

 https://www.novonordisk-us.com/ 

 https://www.novo-pi.com/rybelsus.pdf 

Jan. 16, 2020 7:11 PM ET|About: Novo Nordisk A/S (NVO)|By: Carl Surran, SA News Editor  

 https://seekingalpha.com/news/3532608-novo-nordisk-says-fda-approves-new-indication-for-ozempic 

 BUSINESS NEWSJANUARY 16, 2020 / 6:25 PM / UPDATED 13 HOURS AGO

Carl O'Donnell

3 MIN READ

SAN FRANCISCO (Reuters) - Eli Lilly and Co (LLY.N)

 https://seekingalpha.com/news/3532615-eli-lilly-targets-buying-spree-in-2020 

 https://seekingalpha.com/symbol/LLY 

Fri January 17, 2020 7:30 AM|PR Newswire|About: AGNPR Newswire

DUBLIN, Jan. 17, 2020 /PRNewswire/ -- Allergan plc (AGN)

 https://www.prnewswire.com/news-releases/skinmedica-launches-new-instant-bright-eye-cream-for-immediate-visible-results-300988701.html 

 https://www.allergan.com/ 

Tue January 14, 2020 9:00 AM|GlobeNewswire|About: DNLI

• LRRK2 inhibitor DNL201 Phase 1b demonstrated high levels of target and pathway engagement and improvement of lysosomal biomarkers in patients with Parkinson’s disease 
• LRRK2 inhibitor DNL151 Phase 1 demonstrated high levels of target and pathway engagement and modulation of lysosomal biomarkers in healthy volunteers and continues in an expanded Phase 1b study in patients with Parkinson’s disease
• IND submitted for DNL310 (ETV:IDS) for Hunter syndrome, Denali’s first clinical submission for a large molecule therapeutic enabled by its Transport Vehicle platform technology
• CTA approved for DNL343, a small molecule activator of EIF2B for ALS and other neurodegenerative diseases
• RIPK1 inhibitor DNL747 Phase 1b trials in Alzheimer’s and ALS fully enrolled and open label extension in ALS ongoing with data readouts on track for mid-2020

SOUTH SAN FRANCISCO, Calif., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (DNLI) (NASDAQ: DNLI)

 https://clinicaltrials.gov/ct2/show/NCT04056689 

 https://denalitherapeutics.com/ 

 https://denalitherapeutics.com/partnering 

Wed January 15, 2020 6:59 AM|Business Wire|About: BMY

Application based on results from Part 1 of Phase 3 CheckMate -227 study

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (BMY)

 https://www.bms.com/ 

 https://packageinserts.bms.com/pi/pi_opdivo.pdf 

 https://packageinserts.bms.com/pi/pi_yervoy.pdf 

 https://www.businesswire.com/news/home/20200115005245/en/ 

 https://news.bms.com/press-release/corporatefinancial-news/us-food-and-drug-administration-accepts-priority-review-bris-1 

 https://www.opdivo.com/ 

YERVOY® (ipilimumab) is a prescription medicine used in adults and children 12 years of age and older to treat melanoma (a kind of skin cancer) that has spread (metastatic) or cannot be removed by surgery (unresectable)

 https://www.yervoy.com/ 

Wed January 15, 2020 8:00 AM|Business Wire|About: CLVS

- Clovis seeks U.S. approval for rucaparib as monotherapy treatment for patients with BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer

- FDA submission based on data from TRITON clinical program in advanced prostate cancer

- FDA has assigned PDUFA date of May 15, 2020

BOULDER, Colo.--(BUSINESS WIRE)-- Clovis Oncology, Inc. (CLVS) 

 https://www.clovisoncology.com/ 

 https://www.clovisoncology.com/pipeline/rucaparib/ 

 https://www.businesswire.com/news/home/20200115005158/en/ 

Rubraca® (rucaparib) tablets are a prescription medicine used for:

• The maintenance treatment of adults with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer whose cancer has come back and who are in response (complete or partial response) to a platinum-based chemotherapy
• The treatment of adults with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have certain “BRCA” gene mutations, either inherited (germline) or acquired (somatic), and who have been treated with 2 or more chemotherapy medicines for their cancer. Your healthcare provider will perform a test to make sure Rubraca is right for you

 https://www.rubraca.com/ 

15 January 2020

Issued: Japan and UK

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited 

 https://www.medicines.org.uk/emc/product/10446 

 https://www.dovato.com/ 

Jan. 15, 2020 6:49 AM ET|About: GlaxoSmithKline plc (GSK)|By: Douglas W. House, SA News Editor  

 https://seekingalpha.com/news/3531913-viiv-healthcares-dovato-okd-in-japan 

In two pivotal Phase 3 trials, SPRAVATO®▼ combined with comprehensive standard of care achieved statistically significant rapid reduction of depressive symptoms in patients with major depressive disorder who have current suicidal ideation with intent compared to comprehensive standard of care alone

January 15, 2020 07:40 AM Eastern Standard Time

BEERSE, Belgium--(BUSINESS WIRE)--The Janssen Pharmaceutical Companies of Johnson & Johnson

 https://www.janssen.com/ 

Jan. 15, 2020 7:56 AM ET|About: Johnson & Johnson (JNJ)|By: Douglas W. House, SA News Editor  

 https://seekingalpha.com/news/3531956-j-and-j-files-application-in-europe-for-expanded-use-of-spravato 

 https://www.ema.europa.eu/en/documents/product-information/spravato-epar-product-information_en.pdf 

Thu January 16, 2020 7:00 AM|GlobeNewswire|About: MDT

Pediatric Health System First to Use Groundbreaking Cranial Robotic System in a Patient Surgery

DUBLIN and PHOENIX, Jan. 16, 2020 (GLOBE NEWSWIRE) 

 https://www.phoenixchildrens.org/ 

 https://www.medtronic.com/us-en/index.html 

By Josh Nathan-KazisJan. 13, 2020 11:07 am ET 

 https://www.acastipharma.com/en/investors/news-events/press-releases/detail/173/acasti-pharma-reports-topline-results-for-trilogy-1-phase-3?mod=article_inline 

 https://www.barrons.com/articles/amarin-stock-vascepa-fish-oil-heart-drug-wins-at-the-fda-51576503843?mod=article_inline 

 https://www.astrazeneca.com/media-centre/press-releases/2020/update-on-phase-iii-strength-trial-for-epanova-in-mixed-dyslipidaemia-13012020.html 

 https://amarincorp.com/ 

 https://www.evaluate.com/vantage/articles/news/trial-results/astra-and-acasti-throw-amarin-bulls-more-fodder 

Jan. 13, 2020 6:39 AM ET|About: Acasti Pharma Inc. (ACST)|By: Douglas W. House, SA News Editor 

 https://seekingalpha.com/news/3531176-acasti-pharmas-pain-is-amarins-gain-up-12-premarket?v=1578921724 

Mon January 13, 2020 3:00 AM|PR NewswirePR Newswire

CAMBRIDGE, England, Jan. 13, 2020 /PRNewswire/ -- Exonate,

 https://www.exonate.com/ 

 https://www.prnewswire.com/news-releases/exonate-announces-collaboration-with-janssen-to-develop-a-new-eye-drop-for-the-treatment-of-retinal-vascular-diseases-including-wet-age-related-macular-degeneration-amd-and-diabetic-macular-oedema-dmo-300984951.html 

Jan. 13, 2020 11:24 AM ET|About: Johnson & Johnson (JNJ)|By: Douglas W. House, SA News Editor  

 https://seekingalpha.com/news/3531385-j-and-j-to-collaborate-exonate-in-eye-diseases 

Mon January 13, 2020 8:55 AM|GlobeNewswire|About: EDIT

CAMBRIDGE, Mass. and DALLAS, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (EDIT)

 https://www.editasmedicine.com/ 

 https://www.sandhilltx.com/ 

 https://seekingalpha.com/symbol/EDIT 

Jan. 13, 2020 9:10 AM ET|About: Editas Medicine, Inc. (EDIT)|By: Douglas W. House, SA News Editor  

 https://seekingalpha.com/news/3531295-editas-teams-up-sandhill-therapeutics-in-cancer-shares-up-2-premarket 

Tue January 14, 2020 6:45 AM|PR Newswire|About: LLYPR Newswire

INDIANAPOLIS, Jan. 14, 2020 /PRNewswire/ -- Eli Lilly and Company (LLY)

 https://www.humalog.com/index.aspx 

 https://www.lillyinsulinlispro.com/ 

 https://www.lillydiabetes.com/ 

 https://www.lilly.com/ 

 https://lillypad.lilly.com/entry.php?e=11640 

 https://www.prnewswire.com/news-releases/lilly-expands-insulin-affordability-options-with-lower-priced-versions-of-humalog-mix7525-kwikpen-and-humalog-junior-kwikpen-300986041.html 

Mon January 13, 2020 4:15 PM|GlobeNewswire|About: STML

NEW YORK, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (STML)

 https://stemline.com/ 

 https://bpdcninfo.com/ 

Tue January 14, 2020 8:45 AM|PR Newswire|About: ABBV

PR Newswire

NORTH CHICAGO, Ill., Jan. 14, 2020 /PRNewswire/ -- AbbVie (ABBV)

 More information on this trial can be found at www.clinicaltrials.gov (NCT03478787). 

 https://www.abbvie.com/ 

 https://clinicaltrials.gov/ct2/show/NCT03478787 

 https://www.prnewswire.com/news-releases/new-head-to-head-phase-3-data-show-skyrizi-risankizumab-superior-to-cosentyx-secukinumab-across-primary-and-all-ranked-secondary-endpoints-in-adults-with-moderate-to-severe-plaque-psoriasis-at-52-weeks-300986617.html 

Sun January 12, 2020 4:30 PM|GlobeNewswire|About: IOVA

SAN CARLOS, Calif., Jan. 12, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (IOVA)

 https://www.iovance.com/ 

 https://seekingalpha.com/symbol/IOVA 

Jan. 12, 2020 6:19 PM ET|About: Iovance Biotherapeutic... (IOVA)|By: Douglas W. House, SA News Editor  

 https://seekingalpha.com/news/3531139-iovance-in-licenses-engineered-protein-candidate-from-novartis 

Sun January 12, 2020 10:00 AM|Business Wire|About: ZYME

• Potential for a Novel Chemotherapy-Free Treatment Option for People with Advanced HER2-positive, HR-positive Breast Cancer

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (ZYME)

 https://seekingalpha.com/symbol/ZYME 

 (clinicaltrials.gov: NCT04224272) 

 https://clinicaltrials.gov/ct2/show/NCT02892123?cond=zw25&rank=1 

 https://www.zymeworks.com/ 

 https://www.businesswire.com/news/home/20200112005029/en/ 

Mon January 13, 2020 6:30 AM|PR Newswire|About: LLY

INDIANAPOLIS, Jan. 13, 2020 /PRNewswire/ -- Today, Eli Lilly and Company (LLY) jointly announced with Innovent Biologics

 http://innoventbio.com/#/ 

 https://www.prnewswire.com/news-releases/tyvyt-sintilimab-injection-combined-with-alimta-pemetrexed-and-platinum-met-predefined-primary-endpoint-in-phase-3-orient-11-study-as-first-line-therapy-in-nonsquamous-nsclc-300985366.html 

 https://clinicaltrials.gov/ct2/show/NCT03607539?term=NCT03607539&draw=2&rank=1 

 https://www.lillyoncology.com/ 

Jan. 13, 2020 7:06 AM ET|About: Eli Lilly and Company (LLY)|By: Douglas W. House, SA News Editor  

 https://seekingalpha.com/news/3531196-lillys-tyvyt-alimta-successful-in-lung-cancer-study 

Mon January 13, 2020 6:45 AM|PR Newswire|About: BHC

ARAZLO Lotion Demonstrated Statistically Significant Superiority Over Placebo with Favorable Efficacy, Safety and Tolerability Profile

Post Hoc Analysis of the Two Phase 3 Studies Also Published in JDD

BRIDGEWATER, N.J., Jan. 13, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (BHC) and its dermatology business, Ortho Dermatologics

 https://ortho-dermatologics.com/ 

 https://www.bauschhealth.com/ 

 https://www.prnewswire.com/news-releases/ortho-dermatologics-announces-publication-of-pivotal-phase-3-data-on-arazlo-tazarotene-lotion-0-045-in-the-journal-of-drugs-in-dermatology-jdd-300985477.html 

Mon January 13, 2020 7:30 AM|GlobeNewswire|About: BIIB, PFE

• PF-05251749 is a CNS-penetrant regulator of circadian rhythm with potential to address behavioral and neurological symptoms across various psychiatric and neurological diseases
   
• Biogen to pay Pfizer (PFE) $75 million upfront plus potential milestones of up to $635 million, and royalties
   
• PF-05251749 complements the Company’s pipeline of potential disease-modifying therapies for Alzheimer’s and Parkinson’s diseases

CAMBRIDGE, Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Biogen Inc. (BIIB) today announced an agreement to acquire from Pfizer Inc. PF-05251749

 https://www.biogen.com/ 

 https://www.biogen.com/en_us/pipeline.html 

Mon January 13, 2020 7:00 AM|GlobeNewswire|About: BGNE

- SYLVANT® and QARZIBA®▼ recently listed for fast-track approval in China –

- Expands EUSA’s global product offering; broadens BeiGene’s portfolio –

HEMEL HEMPSTEAD, England and CAMBRIDGE, Mass. and BEIJING, China, Jan. 13, 2020 (GLOBE NEWSWIRE) -- EUSA Pharma (EUSA) and BeiGene, Ltd. (BGNE)

 https://www.eusapharma.com/ 

 https://www.sylvant.com/index.html 

 https://www.beigene.com/science-and-product-portfolio/pipeline 

 https://www.beigene.com/science-and-product-portfolio/research-development 

Thu January 9, 2020 4:01 PM|Business Wire|About: MRNA

New interim analysis after third and final vaccination shows continued boosting of neutralizing antibody titers in both seronegative participants (exceeding seropositive baseline levels 10-fold at 90 and 180 µg) and seropositive participants (exceeding baseline levels by 20- to 40-fold at 90 and 180 µg)

Phase 2 interim data at three months, expected in 2H 2020, intended to inform Phase 3 dose selection

Pivotal Phase 3 study manufacturing and planning already underway; study start expected in 2021

CMV is the most common infectious cause of birth defects in the U.S.; there is no approved vaccine to prevent CMV

Conference call to be held at 8:00 a.m. ET on Friday, January 10, 2020

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Moderna, Inc. (MRNA), (Nasdaq: MRNA) 

 https://www.modernatx.com/ 

 https://www.modernatx.com/pipeline 

 https://www.businesswire.com/news/home/20200109005801/en/ 

 https://seekingalpha.com/symbol/MRNA 

 https://investors.modernatx.com/news-releases/news-release-details/moderna-receives-fda-fast-track-designation-zika-vaccine-mrna 

Fri January 10, 2020 6:59 AM|Business Wire|About: BMY, NKTR

SAN FRANCISCO & NEW YORK--(BUSINESS WIRE)-- Nektar Therapeutics (NKTR) (Nasdaq:NKTR) and Bristol-Myers Squibb Company (BMY) (NYSE:BMY)

 https://www.businesswire.com/news/home/20200110005103/en/ 

 https://packageinserts.bms.com/pi/pi_opdivo.pdf 

 https://www.nektar.com/ 

 https://seekingalpha.com/symbol/NKTR?s=nktr 

 https://seekingalpha.com/symbol/BMY 

Fri January 10, 2020 6:30 AM|PR Newswire|About: DERM, LLY

PR Newswire

INDIANAPOLIS and MENLO PARK, Calif., Jan. 10, 2020 /PRNewswire/ -- Eli Lilly and Company (LLY) and Dermira, Inc. (DERM)

 https://www.dermira.com/ 

 https://investor.lilly.com/news-releases/news-release-details/lilly-announces-agreement-acquire-dermira 

 https://www.prnewswire.com/news-releases/lilly-announces-agreement-to-acquire-dermira-300984850.html 

Jan. 10, 2020 6:44 AM ET|About: Eli Lilly and Company (LLY)|By: Douglas W. House, SA News Editor 

 https://seekingalpha.com/news/3530903-eli-lilly-to-acquire-dermira-for-1_1b 

10 January 2020

Issued: London, UK

 https://viivhealthcare.com/en-gb/media/press-releases/2019/july/viiv-healthcare-presents-positive-96-week-data-from-phase-iii-st/ 

 https://viivhealthcare.com/en-us/ 

 https://www.gsk.com/en-gb/products/ 

Jan. 10, 2020 9:00 AM ET|About: GlaxoSmithKline plc (GSK)|By: Douglas W. House, SA News Editor 

 https://seekingalpha.com/news/3530955-viiv-healthcare-files-fostemsavir-application-in-europe 

 Hong Kong / Health & Environment

• A team of experts will also fly over to the mainland city to be briefed on the situation and learn about control measures
• News comes after China confirms first death from novel coronavirus strain

 Ng Kang-chung

Published: 8:35pm, 12 Jan, 2020

• Secretary for Food and Health Sophia Chan says Hong Kong has plenty of beds and protective gear, but appeals to retailers not to jack up prices of masks

 Victor Ting

Published: 2:21pm, 11 Jan, 2020

 Caixin Global Limited. All Rights Reserved.  

No new cases reported since January 3; World Health Organization praises China’s response to outbreak of mysterious new virus

• Mysterious Lung Disease in China Linked to New Virus in SARS Family, WHO Says
• New Virus in SARS Family May Be Cause of China Pneumonia Outbreak

Sun January 12, 2020 2:00 PM|Business Wire|About: AZN, MRK, MRNA

mRNA-6231 encodes a long-acting selective IL-2 to preferentially expand regulatory T cells that suppress immune activity in autoimmune diseases

mRNA-6981 encodes PD-L1 to treat autoimmune disease, initially to be developed in autoimmune hepatitis

Company to expand pipeline of innovative vaccines in the near term based on clinical success of infectious disease vaccine portfolio to date

CAMBRIDGE, Mass--(BUSINESS WIRE)-- Moderna, Inc. (MRNA)

 https://seekingalpha.com/symbol/MRNA 

 https://www.modernatx.com/pipeline 

 https://www.nasdaq.com/press-release/annual-changes-to-the-nasdaq-biotechnology-index-2019-12-13 

 https://www.modernatx.com/ 

 https://www.businesswire.com/news/home/20200112005052/en/